Shanghai Rightongene Biotechnology Valuation

Q: What is the Fair Price of 688217 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

688217 (CN¥21.5) is trading above our estimate of [[fair value]] (CN¥4.24)

Is 688217 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688217 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 688217 (CN¥21.5) is trading above our estimate of fair value (CN¥4.24)

Significantly Below Fair Value: 688217 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688217?

Key metric: As 688217 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 688217. This is calculated by dividing 688217's market cap by their current revenue.
What is 688217's PS Ratio?
PS Ratio	4.8x
Sales	CN¥249.02m
Market Cap	CN¥1.17b

688217 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4x
Enterprise Value/EBITDA	38.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 688217's PS Ratio compare to its peers?

The above table shows the PS ratio for 688217 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	8x
603716 Thalys Medical Technology Group	1x	n/a	CN¥1.9b
300966 Hubei Goto BiopharmLtd	4.1x	n/a	CN¥2.2b
688163 Shanghai Serum Bio-Technology	11.7x	n/a	CN¥2.2b
300313 Xinjiang Tianshan Animal Husbandry Bio-engineering	15x	n/a	CN¥2.2b
688217 Shanghai Rightongene Biotechnology	4.8x	24.0%	CN¥1.2b

Price-To-Sales vs Peers: 688217 is good value based on its Price-To-Sales Ratio (4.8x) compared to the peer average (8x).

Price to Sales Ratio vs Industry

How does 688217's PS Ratio compare vs other companies in the CN Biotechs Industry?

0 Companies	Price / Sales	Estimated Growth	Market Cap

No more companies available in this PS range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 688217 is good value based on its Price-To-Sales Ratio (4.8x) compared to the CN Biotechs industry average (7.7x).

Price to Sales Ratio vs Fair Ratio

What is 688217's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688217 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	4.8x
Fair PS Ratio	4.1x

Price-To-Sales vs Fair Ratio: 688217 is expensive based on its Price-To-Sales Ratio (4.8x) compared to the estimated Fair Price-To-Sales Ratio (4.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.